Načítá se...
NK cells and CD38: Implication for (Immuno)Therapy in Plasma Cell Dyscrasias
Immunotherapy represents a promising new avenue for the treatment of multiple myeloma (MM) patients, particularly with the availability of Monoclonal Antibodies (mAbs) as anti-CD38 Daratumumab and Isatuximab and anti-SLAM-F7 Elotuzumab. Although a clear NK activation has been demonstrated for Elotuz...
Uloženo v:
| Vydáno v: | Cells |
|---|---|
| Hlavní autoři: | , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
MDPI
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7140687/ https://ncbi.nlm.nih.gov/pubmed/32245149 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cells9030768 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|